» Articles » PMID: 34630738

H19 Overexpression Improved Efficacy of Mesenchymal Stem Cells in Ulcerative Colitis by Modulating the MiR-141/ICAM-1 and MiR-139/CXCR4 Axes

Overview
Journal Dis Markers
Publisher Wiley
Specialty Biochemistry
Date 2021 Oct 11
PMID 34630738
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Overexpression of C-X-C motif chemokine receptor 4 (CXCR4) and intercellular cell adhesion molecule-1 (ICAM-1) may promote homing of mesenchymal stem cells (MSC). In this study, we treated ulcerative colitis animals with MSC preconditioned with or without H19 and compared the therapeutic effect of MSC and MSC-H19. We evaluated the regulatory relationship of H19 vs. miR-141/miR-139 and miR-141/miR-139 vs. ICAM-1/CXCR4. We established an ulcerative colitis mouse model to assess the effect of MSC and MSC-H19. H19 was found to bind to miR-141 and miR-139. The activity of H19 was strongly decreased in cells c-transfected with miR-141/miR-139 and WT H19. ICAM-1 was confirmed to be targeted by miR-141 and CXCR4 was targeted by miR-139. The H19 expression showed a negative regulatory relationship with the miR-141 and miR-139 expression but a positive regulatory relationship with the ICAM-1 and CXCR4 expression. In summary, the overexpression of H19 in MSC downregulated miR-139 and miR-141, thus increasing the activity of their targets ICAM-1 and CXCR4, respectively, to exhibit therapeutic effects in ulcerative colitis.

Citing Articles

Pharmacokinetic characteristics of mesenchymal stem cells in translational challenges.

Shan Y, Zhang M, Tao E, Wang J, Wei N, Lu Y Signal Transduct Target Ther. 2024; 9(1):242.

PMID: 39271680 PMC: 11399464. DOI: 10.1038/s41392-024-01936-8.


The significance of long non-coding RNAs in the pathogenesis, diagnosis and treatment of inflammatory bowel disease.

Jiang F, Wu M, Li R Precis Clin Med. 2024; 6(4):pbad031.

PMID: 38163004 PMC: 10757071. DOI: 10.1093/pcmedi/pbad031.


Therapeutic potential of mesenchymal stem/stromal cells (MSCs)-based cell therapy for inflammatory bowel diseases (IBD) therapy.

Saadh M, Mikhailova M, Rasoolzadegan S, Falaki M, Akhavanfar R, Gonzales J Eur J Med Res. 2023; 28(1):47.

PMID: 36707899 PMC: 9881387. DOI: 10.1186/s40001-023-01008-7.

References
1.
Caplan A . New MSC: MSCs as pericytes are Sentinels and gatekeepers. J Orthop Res. 2017; 35(6):1151-1159. DOI: 10.1002/jor.23560. View

2.
Ren G, Zhao X, Zhang L, Zhang J, LHuillier A, Ling W . Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol. 2010; 184(5):2321-8. PMC: 2881946. DOI: 10.4049/jimmunol.0902023. View

3.
Li X, Wang Q, Ding L, Wang Y, Zhao Z, Mao N . Intercellular adhesion molecule-1 enhances the therapeutic effects of MSCs in a dextran sulfate sodium-induced colitis models by promoting MSCs homing to murine colons and spleens. Stem Cell Res Ther. 2019; 10(1):267. PMC: 6708236. DOI: 10.1186/s13287-019-1384-9. View

4.
Bennett C, Kornbrust D, Henry S, Stecker K, Howard R, Cooper S . An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J Pharmacol Exp Ther. 1997; 280(2):988-1000. View

5.
Baumgart D, Sandborn W . Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007; 369(9573):1641-57. DOI: 10.1016/S0140-6736(07)60751-X. View